ArticleJournal of tropical medicine2026
ABO Blood Groups and Clinical Outcomes in Crimean-Congo Hemorrhagic Fever: Insights From a Large Turkish Cohort.
Article in Journal of tropical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne viral disease in which host-related factors contributing to disease susceptibility and clinical outcomes remain incompletely understood. We aimed to evaluate the impact of ABO and Rh blood groups on susceptibility and prognosis in patients with CCHF and to investigate their relationship with epidemiological characteristics in a large real-world cohort. This retrospective study included 1143 adult patients with PCR-confirmed CCHF who were followed at our center between April 2015 and September 2024. ABO and Rh blood groups were determined using the Hitachi ElecSys 2010 Rack system, and hematological, biochemical, and coagulation parameters were evaluated simultaneously with CCHF PCR testing at hospital admission. Clinical outcomes, viral load, epidemiological characteristics, disease severity according to the Severity Grading Score (SGS), and laboratory findings were compared among blood groups. In addition, multivariable logistic regression analysis was performed to identify independent predictors of in-hospital mortality. Of the 1143 patients, 732 (64.0%) were male and 411 (36.0%) were female; 548 patients had blood group A, 353 group O, 154 group B, and 88 group AB. Overall in-hospital mortality was 8.5% (97/1143). No significant differences were observed among ABO or Rh blood groups regarding in-hospital mortality, intensive care unit (ICU) requirement, viral load, or reported tick exposure. Although no deaths or ICU admissions occurred in the AB Rh-negative subgroup, this subgroup comprised only 13 patients. Significant differences were identified only in amylase and lipase levels among blood groups, whereas SGS, ferritin, interleukin-6, and other laboratory parameters were comparable. In the multivariate analysis, ABO and Rh blood groups were also not independently associated with in-hospital mortality. These findings suggest that ABO and Rh blood groups are not associated with clinically meaningful differences in disease severity or prognosis in patients with CCHF. Further multicenter prospective studies are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.